人脐带血间充质干细胞治疗膝关节骨关节炎疗效研究  

Effect of human umbilical cord blood mesenchymal stem cells in the treatment of knee osteoarthritis

作　　者：孙月 刘欣伟 向杜磊 赵根 李涵 金文铭 SUN Yue;LIU Xin-wei;XIANG Du-lei;ZHAO Gen;LI Han;JIN Wen-ming(Room of Medical Information&Data,General Hospital of Northern Theater Command,Shenyang 110016,China)

机构地区：[1]北部战区总医院医学信息数据室,辽宁沈阳110016 [2]北部战区总医院骨科,辽宁沈阳110016 [3]中国医科大学北部战区总医院研究生培养基地,辽宁沈阳110016 [4]锦州医科大学北部战区总医院研究生联合培养基地,辽宁沈阳110016 [5]大连医科大学北部战区总医院研究生联合培养基地,辽宁沈阳110016

出　　处：《创伤与急危重病医学》2022年第1期7-10,共4页Trauma and Critical Care Medicine

基　　金：沈阳联勤保障中心自选科研项目(2020-485)。

摘　　要：目的探讨人脐带血间充质干细胞(UC-MSCs)治疗膝关节骨关节炎的临床疗效和安全性。方法选取自2018年1月至2019年5月收治的48例膝关节骨关节炎患者为研究对象。根据随机数字表法将患者分为UC-MSCs组和安慰剂组,每组各24例。UC-MSCs组患者给予膝关节腔内注射UC-MSCs治疗,安慰剂组患者膝关节腔内注射生理盐水。随访12个月,比较两组患者的WOMAC、Lysholm评分;观察两组患者注射UC-MSCs后的软骨缺损变化情况以及安全性等。结果治疗6、12个月,UC-MSCs组患者的WOMAC评分均较治疗前明显下降,Lysholm评分均较治疗前明显提高,差异有统计学意义(P<0.05);安慰剂组患者的WOMAC、Lysholm评分与治疗前比较,差异均无统计学意义(P>0.05)。治疗6、12个月,UC-MSCs组患者的WOMAC评分均明显低于安慰剂组,Lysholm评分均明显高于安慰剂组,差异有统计学意义(P<0.05)。随访12个月,两组患者均未发现严重不良事件。结论膝关节腔内注射UC-MSCs治疗膝关节骨关节炎疗效较佳,且安全性较高。Objective To investigate the clinical efficacy and safety of umbilical cord blood mesenchymal stem cells(UC-MSCs)in the treatment of knee osteoarthritis.Methods A retrospective study was performed on 48 cases of patients with knee osteoarthritis from January 2018 to May 2019.The patients were randomly divided into UC-Mscs group and placebo group.Patients in the UC-MSCs group were treated with intracavitary injection of UC-MSCs,and patients in the placebo group were treated with intracavitary injection of normal saline.After 12 months of follow-up,WOMAC and Lysholm scores were compared between the two groups.The safety and changes of cartilage defects after UC-MSCs injection were observed in the two groups.Results After 6 and 12 months of treatment,the WOMAC score of UC-MSCs group were significantly lower than before treatment,and Lysholm score of UC-MSCs group were significantly higher than before treatment(P<0.05).There were no significant differences in WOMAC and Lysholm scores in placebo group compared with before treatment(P>0.05).After 6 and 12 months of treatment,the WOMAC score of UC-MSCs group was significantly lower than that of placebo group,and Lysholm score was significantly higher than that of placebo group,with statistically significant differences(P<0.05).After 12 months of follow-up,no serious adverse events were found in both groups.Conclusion UC-MSCs intravenously injected into the knee for the treatment of knee osteoarthritis has good efficacy and high safety.

关 键 词：膝关节 骨关节炎 脐带血间充质干细胞 

分 类 号：R684.3[医药卫生—骨科学]